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Abstract
The potential of broadly neutralizing antibodies targeting the HIV-1 envelope trimer to pre-
vent HIV-1 transmission has opened new avenues for therapies and vaccines. However,
their implementation remains challenging and would profit from a deepened mechanistic
understanding of HIV-antibody interactions and the mucosal transmission process. In this
study we experimentally determined stoichiometric parameters of the HIV-1 trimer-antibody
interaction, confirming that binding of one antibody is sufficient for trimer neutralization. This
defines numerical requirements for HIV-1 virion neutralization and thereby enables mathe-
matical modelling of in vitro and in vivo antibody neutralization efficacy. The model we devel-
oped accurately predicts antibody efficacy in animal passive immunization studies and
provides estimates for protective mucosal antibody concentrations. Furthermore, we derive
estimates of the probability for a single virion to start host infection and the risks of male-to-
female HIV-1 transmission per sexual intercourse. Our work thereby delivers comprehen-
sive quantitative insights into both the molecular principles governing HIV-antibody interac-
tions and the initial steps of mucosal HIV-1 transmission. These insights, alongside the
underlying, adaptable modelling framework presented here, will be valuable for supporting
in silico pre-trial planning and post-hoc evaluation of HIV-1 vaccination or antibody treatment
trials.
Author summary
Successful solicitation of the potential of neutralizing antibodies for HIV-1 prevention
will require a deepened understanding of HIV-1 transmission and antibody neutraliza-
tion. In this study, we experimentally determined molecular parameters of the HIV-1-
antibody interaction, and subsequently used this knowledge to devise a mathematical
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model of HIV-1 infection and antibody neutralization in vivo. First, we experimentally
confirmed that binding of one antibody per HIV-1 envelope trimer is sufficient for trimer
neutralization. This finding, in combination with the number of trimers per HIV-1 virion,
the number of trimers required for virus entry, and the affinity of antibody-trimer bind-
ing, enabled precise modelling of HIV-1 antibody neutralization. We employed our
model for a post-hoc analysis of non-human primate infection studies, thereby obtaining
estimates of HIV-1 neutralization in vivo and the probability for a single HIV-1 virion to
initiate host infection. We further modelled HIV-1 infection and antibody neutralization
during male-to-female transmission in the human host, which delivered estimates for the
likelihood of HIV-1 transmission per sexual act and predictions of protective mucosal
antibody concentrations. The quantitative insights into HIV-1 infection and antibody
neutralization derived here, spanning from the molecular to the systemic level, contribute
to a refined understanding of HIV-1 transmission and may prove useful for pre-study
planning or post-hoc analyses of HIV-1 clinical trials and vaccine studies.
Introduction
Recent years have seen tremendous success in the isolation and characterization of broadly
neutralizing antibodies (bnAbs) from selected HIV-1 infected patients. By binding to the HIV-
1 envelope glycoprotein trimer (Env), bnAbs succeed to neutralize a majority of circulating
HIV-1 strains. It is assumed that the elicitation of antibodies will constitute a crucial compo-
nent of a successful HIV-1 vaccination strategy, and known bnAbs are intensely explored as
templates for HIV-1 vaccine development [1–5]. Indeed, it has been conclusively demon-
strated in animal models that passive immunization with bnAbs can protect against virus chal-
lenge, delay viral rebound and transiently lower viremia [6–19]. Furthermore, passive
immunization in human patients demonstrated an impact of bnAbs on established HIV-1
infection [20–22], underscoring the potential relevance of bnAbs to prevent or treat HIV-1
infection.
However, despite this wealth of information on the protective effects of bnAbs in vivo, key
parameters of the HIV-1 nAb interaction and HIV-1 host-to-host transmission remain ill-
defined. This concerns both fundamental molecular aspects of Env trimer-nAb binding and
systemic factors of mucosal HIV-1 transmission. Importantly, comprehensive knowledge of
the molecular and systemic parameters governing HIV-1 transmission and nAb neutralization
would empower in silico modelling of nAb activity and be instrumental to guide vaccine devel-
opment or nAb treatment trials [23, 24]. We thus propose that precise numerical quantifica-
tion of the parameters that steer nAb efficacy and in vivo HIV-1 transmission is needed.
Moving towards this aim, we report here on a combined experimental-mathematical analysis
providing comprehensive quantitative insight into mucosal HIV-1 transmission and nAb neu-
tralization (Fig 1).
Starting at the molecular level, the first question we addressed regards the number of nAbs
required to neutralize each HIV-1 Env trimer (the stoichiometry of neutralization, N). This
number, in combination with the mean number of trimers per HIV-1 virion (Z) and the num-
ber of trimers required for virus entry (T, Fig 1A) defines the number of nAbs needed to neu-
tralize single HIV-1 virions or entire virion populations [25–31]. While such stoichiometric
definitions may appear academic given the well-known potential of nAbs to neutralize HIV-1,
we show here that these parameters are indeed crucial for an in-depth understanding of HIV-1
nAb neutralization and enable mathematical predictions of nAb neutralization potency.
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Moving to the systemic level, we next addressed uncertainties in our understanding of
mucosal HIV-1 transmission. Non-human primate studies revealed the interplay between nAb
potency, in vivo nAb concentrations, and the resulting susceptibility or protection against
virus infection [6–19]. However, a detailed systemic understanding of the mucosal infection
process and the factors resulting in nAb protection from infection, ideally down to the single-
virion level, are missing. Utilizing our stoichiometric model framework we performed a post-
hoc analysis of selected animal studies, and obtained precise quantitative insight into mucosal
Fig 1. Parameters governing the interaction between HIV-1 and neutralizing antibodies and study layout. (A) Molecular parameters
included in this study to define HIV-1 infectivity and nAb neutralization. (B) Parameters included in this study to define in vivo HIV-1 infection
and nAb neutralization. All parameters used for modelling are highlighted in bold and are summarized in S1 Table. Parameters estimated in
this study, notably the stoichiometry of trimer neutralization, N, and the probability of an infectious virion to start a host infection,ψ, are
highlighted in red. (C) Shown here is the sequence of experimental and mathematical analyses in this study, starting with the experimental
estimation of N and extending to the modelling of human mucosal HIV-1 transmission.
https://doi.org/10.1371/journal.ppat.1006313.g001
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nAb neutralization and the probability for single infectious HIV-1 virions to establish a sys-
temic host infection.
Lastly, significant uncertainty is associated with the process and the probabilities of mucosal
HIV-1 transmission in the human host via sexual contact. Per-exposure risk estimates of HIV-
1 transmission vary widely, and uncertainty prevails regarding the concentration of nAbs in
genital mucosal tissues that would provide protection from infection. This is not surprising,
given the difficulties in estimating these parameters directly in the human population [32, 33].
Thus, in a final step we build on all previously determined parameters to model human HIV-1
penile-vaginal transmission. This analysis yielded predictions of HIV-1 male-to–female per
intercourse transmission probabilities that match empirical data, and provided estimates of
mucosal nAb concentrations expected to provide protection from HIV-1 infection.
Results
We devised an experimental and mathematical framework to analyze interactions between
HIV-1 virions and nAbs both on a molecular level and during HIV-1 transmission in vivo.
Specifically, we (i) investigated the stoichiometric parameters of nAb binding to Env trimers
on virions leading to neutralization, (ii) modelled nAb neutralization and HIV-1 infectivity
both in vitro and in macaque passive nAb immunization virus challenge studies, and (iii) mod-
elled HIV-1 transmission risk and protective effects of nAbs in the human host during penile-
vaginal sexual contact. Our model framework relies on a defined set of parameters, retrieved
from the literature or determined in this study (Fig 1A and 1B and S1 Table). Within our ana-
lytical framework, we conceptualize HIV-nAb interactions as follows:
(i). To model whether an HIV-1 virion to which a certain number of nAbs are bound is
still infectious we expand previously developed stoichiometric models [26, 29, 31, 34,
35]. These models rely on the distribution of Env trimer numbers among HIV-1 viri-
ons (η), the number of trimers required for virus entry into a target cell (the entry stoi-
chiometry, T) and the number of Env trimer subunits that nAbs must bind to
neutralize the trimer (the neutralization stoichiometry, N). With these parameters we
determine the average number of nAbs required for HIV-1 virion neutralization.
(ii). To transfer the number of nAbs required for virion neutralization into the more mean-
ingful parameter of nAb concentration, we utilize nAb trimer binding affinity, KD. We
model the nAb-Env interaction as a binding reaction depending on nAb trimer bind-
ing constant (KD) and nAb concentration (cAb).
(iii). Modelling the impact of nAbs in preventing mucosal HIV-1 transmission requires
knowledge of nAb concentrations at the port of entry (cAb in vaginal secretions and tis-
sue), the HIV-1 inoculum size (nin), the probability of virions to penetrate the epithelial
layers (ppen) and the probability that one infectious virion successfully initiates host
infection (ψ).
In Fig 1C, we depict the sequence of experimental and mathematical approaches in this
study, highlighting the parameters required for each successive modelling step.
Estimating the stoichiometry of HIV-1 trimer neutralization, N
The topic of HIV-1 neutralization stoichiometry has previously been studied experimentally
and computationally, with N = 1 being the most common conclusion [26, 29, 34]. However,
ambiguity in these estimates prevailed, predominantly due to previously poorly defined
parameters of HIV-1 entry stoichiometry, T, and mean virion trimer number, Z, which are
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essential for the analysis of N [27–29]. Here, we utilized recently determined values of T and Z
[28] to conclusively estimate N across different HIV-1 strains and bnAbs identified in recent
years, for which estimates of N are currently lacking. As precise information on N across nAbs
is indispensable for an in-depth numerical understanding of HIV-1 nAb neutralization (Fig
1A), we set out to estimate N for a range of nAbs and HIV-1 strains.
To estimate N, we measured nAb neutralization of HIV-1 pseudoviruses carrying mixed
trimers of nAb-sensitive and resistant Envs and analyzed the data with mathematical models
(Fig 2A). Relative virus infectivities (RI) under saturating nAb concentrations were set in rela-
tion to the fraction of resistant Env (fR), shown for nAb 2F5 with Envs JR-FL wt (2F5 sensitive)
and mutant JR-FL D664N (2F5 resistant) (Fig 2B, S1 Fig, S2 Table). Taking the JR-FL entry
stoichiometry (T = 2) and mean trimer number per virion (Z ¼ 11:8) into account (S3 Table),
our model predicts different RI profiles for different N (Fig 2C). Mathematical analysis of the
experimental data indicated a neutralization stoichiometry of N = 1 for JR-FL by nAb 2F5 (Fig
2C). We confirmed the robustness of the N = 1 estimate against variation in virus entry stoichi-
ometry (T) and mean virion trimer number (Z) by sensitivity analyses (Fig 2D). To investigate
the observed deviations of the model fit from the experimental data (Fig 2C), we performed a
goodness-of-fit analysis (Fig 2E). This analysis indicated that lower values of T and/or Z could
result in better curve fits. While we expect T to be constant for each viral strain, fluctuations in
Z from experiment to experiment are conceivable and provide a potential explanation for the
deviation between experimental data and model predictions. In addition, mean virion trimer
numbers of a given virus preparation may decrease over time as spontaneous Env shedding
can occur resulting in non-functional trimers [36].
Fig 2. Estimating the stoichiometry of HIV-1 nAb neutralization (N) with mixed trimer assays. (A) Scheme depicting the combined
experimental-mathematical approach employed here to estimate N. (B) Neutralization by nAb 2F5 of mixed trimer HIV-1 pseudovirus stocks
containing the indicated ratios of JR-FL wt (2F5 sensitive) and JR-FL D664N (2F5 resistant) Envs. The relative infectivity (RI) of each stock
is given by the percentage of target cell infection (i.e., the inverse of % neutralization) under saturating 2F5 nAb concentrations. (C)
Theoretical model predictions of the relation between N (N = 1, 2 or 3; colored lines) and RI of virus stocks with different fractions of
neutralization-sensitive to resistant Env (fR). The experimental JR-FL nAb 2F5 RI data from (B) are plotted as black dots, representing two
independent experiments. Data fitting resulted in an estimate of N = 1, assuming T = 2 and Z ¼ 11:8 trimers for each JR-FL virion (S3 Table).
(D) Robustness analysis for the N = 1 estimate of HIV-1 strain JR-FL and nAb 2F5 against variation in T and Z. Blue areas show
combinations of T and Z resulting in estimates of N = 1, green areas show combinations of T and Z that would result in estimates of N = 2.
The actual values of T and Z for JR-FL (see above) are marked by the white dot, indicating that the N = 1 estimate is robust. (E) Since the
model fit shown in (C) for JR-FL and nAb 2F5 is imperfect, we analyzed the goodness-of-fit. A slightly reduced Z or slightly increased T
compared to those used for the analysis (white dot, S3 Table) could improve the model fit to the experimental data.
https://doi.org/10.1371/journal.ppat.1006313.g002
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To further test variation in T and Z on predictions of N, we assessed N for nAb 2F5 against
Env variants of HIV-1 strains JR-FL and NL4-3 that differ in T or Z (S2A–S2F Fig, S3 Table)
[28, 37]. We indeed observed divergent RI profiles upon variation in T or Z as predicted by
our model. However, for all Env variants tested we retrieved estimates of N = 1.
To explore if nAb avidity influences estimation of N, we compared nAb 2F5 IgG and Fab
fragment. Both yielded overlapping RI profiles for strains JR-FL and NL4-3 and identical
estimates of N = 1 (S2G–S2I Fig), confirming that estimation of N is independent of nAb
valency.
NAb binding to a single Env subunit is sufficient for trimer neutralization
Having validated our approach to estimate N (Fig 2), we sought to obtain a comprehensive
analysis of N for various HIV-1 nAbs including VRC01, NIH45-46, PGV04, b12, PGT121,
PGT128, PGT135, 2G12, PG9, PGT145, and 2F5 (S4 Table). We therefore generated a panel of
Env mutants in five divergent HIV-1 strains with single or combined nAb resistance mutations
(S1 Fig). Several of these Env mutants showed a significant reduction in virus infectivity (S2
Table). This is critical to note, as matched virus entry parameters, notably T and Z, are a pre-
requisite for the analysis of N (S2 Fig). Indeed, we observed that strong infectivity differences
between nAb-resistant and sensitive Envs in mixed trimer assays result in substantial devia-
tions of the RI profiles that prohibit determination of N (S3 Fig). We thus restricted our analy-
sis to mixed trimer assays with nAb sensitive-resistant Env pairs of comparable infectivity
( 2-fold infectivity difference). In a direct comparison of eight different nAbs across five Env
mixed trimer combinations, we thereby obtained a consistent estimate of N = 1 irrespective of
nAb epitope specificity, potency or HIV-1 strain (Fig 3A–3E, S4 Fig). The estimate of N = 1
was confirmed by bootstrap analyses (S5 Fig) and goodness-of-fit plots across all analyzed
Env-nAb pairings (S6 Fig). As shown before (Fig 2E), the goodness-of-fit would in many cases
be improved for lower values of T and/or Z, possibly indicating slight deviations in these
parameters within the experimental setup.
In the above analysis we employed a hard threshold model in which, according to our anal-
yses, binding of one nAb to a trimer results in complete loss of function. Soft threshold models,
which allow for partial loss of trimer functionality upon nAb binding, were introduced in ear-
lier studies by us and others [26, 29]. To investigate how a soft threshold model would fit to
our current data set, we re-analyzed our data accordingly [26]. Here, we allow the probability
of a virion to infect a cell to scale with the number of functional trimers (a soft threshold for
virus entry) and the functionality of a trimer to decrease by successive nAb binding (a soft
threshold for neutralization). Our analysis revealed that the functionality loss of a trimer upon
nAb binding to one subunit is dominant, that is, a soft threshold model is not supported (S7
Fig). This finding thereby underscores the assumption of a hard threshold for the stoichiome-
try of HIV-1 nAb neutralization.
To validate that N = 1 across all nAbs tested here, we tested a set of nAbs targeting different
epitopes against Env variants with multiple nAb escape mutations, allowing parallel analysis of
diverse nAbs on the same set of mixed trimer virus stocks (Fig 3F and 3G, S8 Fig, S2 Table).
Two Env combinations (Fig 3F and 3G) were infectivity matched and allowed mathematical
analysis of N, yielding N = 1 for all nAbs tested. To derive an estimate of N in the non-infectiv-
ity matched setups we included nAb 2F5 throughout, as we previously established that it neu-
tralizes with N = 1 (Fig 2). Furthermore, nAb PG9, which is known to bind with only one nAb
per trimer [38, 39], was included in two of these setups (S8 Fig). As 2F5 and PG9 yielded highly
similar curves compared to the other nAbs, we conclude that our analysis univocally inferred
N = 1 for all probed nAbs.
Predicting HIV-1 antibody neutralization in vivo
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Regarding this consistent N = 1 estimate across all nAbs tested, we asked whether non-anti-
body Env inhibitors would show a similar neutralization behaviour. To test this, we generated
Env mutants resistant against the peptide T-20, a clinically used HIV-1 entry inhibitor target-
ing the Env gp41 subunit [40]. Using mixed trimer assays, we found that T-20 neutralizes with
an N = 1 stoichiometry (S9 Fig). This indicates that, regardless of inhibitor type, interference
with one Env trimer subunit is sufficient for HIV-1 trimer neutralization.
Antibodies in HIV-1+ patient plasma neutralize with a N = 1 stoichiometry
Antibody responses in the majority of HIV-1 infections are largely ineffective in neutralizing
the virus within the patient, and bear only limited neutralization potency and breadth against
other HIV-1 strains. In contrast, the bnAbs available to date were isolated from rare HIV-1+
patients with high HIV-1 neutralization potency and breadth [41–43]. In our stoichiometry
analysis, these bnAbs uniformly showed N = 1 (Fig 3A–3G). This raises the question if
weakly neutralizing Abs as most commonly elicited during HIV-1 infection require a higher
N, and whether N = 1 is a distinguishing feature of bnAbs. To test this, we determined N of
Fig 3. N = 1 is a general feature of broadly neutralizing antibodies and polyclonal HIV-1+ patient plasma IgG. (A) to (E) Mixed trimer
neutralization setups with the Envs and nAbs indicated in each panel, yielding estimates of N = 1 in all cases. (F) to (G) Envs with multiple
nAb resistance mutations allowed parallel assessment of various nAbs on the same set of mixed trimer virus stocks. Mathematical analysis
indicated N = 1 in all cases. (H) Mixed trimer setup with Envs ZA110 wt and ZA110-V1V21.7, the latter being sensitive to autologous HIV-1+
patient plasma. The model fit to the experimental data (black dots) yielded a plasma neutralization stoichiometry of N = 1. (I) Mixed trimer
setup with Envs ZA110 wt and ZA110 ΔV1V2 and nAbs b6, 17B and 48D and three heterologous HIV-1+ patient plasma (Pat117, Pat118
and Pat122). The Envs in this setup are not infectivity-matched precluding mathematical analysis, but graphic comparison indicates equal N
of nAbs and patient plasma. (J) Mixed trimer setup with Envs JR-FL L175P and JR-FL P369L M373R D664N and nAbs b6, 1.79, 2F5, b12
and heterologous patient plasma SP122, yielding equal estimates of N = 1. All data points depict two independent experiments. (K) N = 1 is a
universal feature of all anti-HIV nAbs tested here. This defines decisive numerical requirements of HIV-1 virion neutralization by antibodies.
https://doi.org/10.1371/journal.ppat.1006313.g003
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the polyclonal antibody mix in HIV-1+ patient plasma. We first tested plasma from an indi-
vidual with typical HIV-1 neutralization escape [44] and corresponding plasma neutraliza-
tion-resistant and sensitive Env variants (ZA110 wt and ZA110-V1V21.7, respectively; S2
Table). Mixed trimer assays yielded N = 1 for the plasma Abs of this individual (Fig 3H). We
further tested plasma from three chronically HIV-1 infected individuals (Pat117, Pat118,
Pat122) showing only weak HIV-1 neutralization activity. We tested these plasma on mixed
trimer stocks of Envs ZA110 wt (resistant) and ZA110 ΔV1V2 (sensitive) and further
included weakly neutralizing Abs b6, 17b and 48d in this analysis (Fig 3I). Comparison of
the RI profiles indicated identical N for all probed plasma and nAbs. Additionally, plasma
Pat122 neutralized HIV-1 strain JR-FL in an infectivity-matched setup with N = 1, as did sev-
eral nAbs (Fig 3J).
Thus, irrespective of nAb potency, breadth or epitope specificity, neutralization of HIV-1
trimers requires only a single Env subunit to be bound by antibody (Fig 3K). This estimation
of N defines numerical requirements for HIV-1 antibody neutralization [27, 29–31, 45], which
we employed in subsequent modelling steps to assess HIV-1 virion population neutralization
in vitro and in vivo.
In silico prediction of nAb inhibitory capacity
We previously established a mathematical framework that predicts the number of nAbs
required to neutralize a given HIV-1 virion population based on the stoichiometry parameters
N, T and Z [27]. The conclusive estimation of N (Figs 2 and 3), together with previously deter-
mined parameters T and Z [28], now enabled us to use our framework for quantitative predic-
tions of nAb neutralization. We extended the framework by including the affinity of nAb
binding to Env trimers (represented by the binding constant, KD) [35, 46] to predict the frac-
tion of neutralized HIV-1 virions for given nAb concentrations. In essence, this allowed us to
simulate HIV-1 nAb neutralization curves in silico (Fig 4A).
For this analysis we utilized nAb binding constants, KD, recently reported for the HIV-1
strain BG505 SOSIP trimer [49]. We employed these KD values together with T and Z of
BG505 (S3 Table) and N = 1 to model nAb neutralization of an HIV-1 BG505 virion popula-
tion (Fig 4B–4D). As expected, we found that nAbs with high Env binding affinity (low KD)
are predicted to require lower concentrations to achieve virion population neutralization (Fig
4B). The required nAb concentrations increase slightly with fewer trimers needed for HIV-1
entry (low T) (Fig 4C) and higher virion trimer content (high Z) (Fig 4D). The latter two trends
can be rationalized as follows: in both cases (a small T or a high Z), more nAbs will be needed
to neutralize a given virion population, resulting in higher predicted nAb concentrations.
The relation between nAb trimer binding and HIV-1 virion population neutralization is
influenced by all parameters included in our model (Fig 4A). Especially the influence of T and
Z on nAb neutralization predictions should not be underestimated. This is highlighted in Fig
4E, depicting estimated values of nAb concentrations required for 50% virus population neu-
tralization (IC50) in dependence on T and Z.
In addition to predicting nAb neutralization curves and IC50 values, we determined nAb
concentrations required to achieve sterilizing neutralization of HIV-1 virion populations. Due
to unproductive nAb binding to Env trimers (Fig 4H) [27], the fraction of Env subunits
required to be bound by nAb for sterilizing neutralization of a virion population increases
with virion population size (Fig 4F). Likewise, the predicted nAb concentrations required for
sterilizing neutralization of virion populations increase with virion population size (S10A–
S10C Fig). As shown in Fig 4B–4D for nAb neutralization curves, these nAb concentrations
are influenced by nAb KD, T and Z (S10A–S10C Fig). Of note, only nAb KD has a direct linear
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Fig 4. Predicting HIV-1 antibody neutralization curves and IC50. (A) Scheme depicting the virus and nAb-specific parameters
necessary to predict HIV-1 neutralization by nAbs in silico. (B) to (D) Predicted HIV-1 nAb neutralization curves in dependence of (B) nAb
KD, (C) HIV-1 entry stoichiometry, T, and (D) mean viron trimer number, Z. (E) Dependence of nAb IC50 on the number of Env trimers
required for HIV-1 cell entry, T. (F) Relation between HIV-1 virion population size and the fraction of Env subunits that need to be bound by
nAb to achieve virus population neutralization. (G) Comparison of experimental nAb IC50 values measured with HIV-1 strain BG505 [47, 48]
(S5 Table) and IC50’s predicted by our model using BG505-specific T, Z and KD [49] values (S3 and S5 Tables). For nAb PGT145 we
assumed that only 1 nAb can bind per trimer; the PGT145 IC50 estimates with the 3-nAb-per-trimer model, used for all other nAbs, are
Predicting HIV-1 antibody neutralization in vivo
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relationship with sterilizing nAb concentrations, while the influence of T and Z follows non-
linear relations (S10D–S10F Fig).
We noted that our predicted neutralization curves show steeper slopes than commonly
observed in HIV-1 neutralization assays (S11A Fig). We thus asked which parameters of our
model could explain this deviation, and found that assuming broader virion trimer number
distributions (i.e., higher variance in trimer numbers between virions) results in less steep pre-
dicted neutralization curves (S12 Fig). Of note, we also observed that our predicted curves are
in closer agreement to in vitro neutralization data obtained with replication-competent virus
and PBMC target cells (S11B Fig). While a detailed analysis of this relation and the underlying
parameters is beyond the scope of this manuscript, this observation may be taken as indication
that our model predicts neutralization curves better for replication-competent virus than for
pseudovirus preparations.
To test the predictive power of our in silico approach, we compared experimentally derived
IC50 values of HIV-1 strain BG505 and nAbs VRC01, PGV04, PGT121, PGT123, PGT145 and
2G12, originating from in vitro experiments by three independent laboratories [47–49], with
nAb IC50 values estimated by our model (Fig 4G, S11 Fig, S5 Table). Our predicted IC50 val-
ues for nAbs VRC01 and PGT121 were in close agreement with the measured values. For
nAbs PGT123 and 2G12, we observed wide variations in experimentally derived IC50 values;
interestingly, the IC50 values predicted by our model lay in between these values. For nAbs
PGV04 and PGT145, our estimated IC50s are slightly lower and higher than experimentally
determined IC50s, respectively, though not far off (see below for a detailed discussion of the
PGT145 IC50 estimation). This good agreement between experimental and predicted nAb
IC50s highlights that the parameters included in our model (N, T, Z, nAb KD and nAb concen-
tration) capture relevant steps of HIV-1 virion neutralization. Of note, our model performs
significantly better than a simpler model based on nAb KD alone (S13 Fig).
We also derived predictions of nAb neutralization for scenarios of N = 1 but assuming that
exclusively one nAb can bind one of the three epitopes displayed on each trimer (a binding
behavior described for nAbs PG9, PG16 or PGT145 [38, 39, 49]). We compared these predic-
tions to our standard model where we assume that all three trimer subunits can potentially be
bound, although only one Env subunit needs to be bound to achieve neutralization. In this
case, binding of the second and third nAb represents unproductive binding of nAbs, since the
trimer is already neutralized by binding of the first nAb (Fig 3K). Importantly, we assume that
also for PG9-like nAbs, initially the same number of epitopes is present as for “typical” nAbs
(i.e., three per trimer), with the difference that binding of PG9-like nAbs shows negative coop-
erativity: after binding of the first antibody the remaining two epitopes are inaccessible. In our
analysis, we assume two nAbs with the same KD for their protomeric epitopes, but either a
three-nAb-per-trimer or one-nAb-per-trimer binding behavior (Fig 4H). According to our
predictions, binding of only one nAb per trimer results in a 2-fold decreased IC50, thereby
demonstrating the effect of unproductive nAb binding (Fig 4H). Intriguingly, the PGT145
IC50 predictions using this model are closer to experimental PGT145 IC50 values than the pre-
dictions obtained with the standard model (Fig 4G). This indicates that nAbs with a one-nAb-
shown in light grey (see also panel H). (H) For most nAbs, we assume that three nAbs can bind each trimer, while binding of one nAb is
already sufficient for neutralization (N = 1). Binding of nAbs to a trimer that is already neutralized constitutes unproductive binding and may
reduce antibody concentrations to a subcritical level [27]. To quantify this effect, we predicted neutralization by two nAbs with equal KD, but
assuming that either three nAbs can bind each trimer, or that nAb binding is anti-cooperative as observed for PG9/PGT145-like nAbs, which
are known to occupy only one of three potential epitopes per trimer. We observed a slight neutralization advantage for PG9/PGT145-like
nAb binding behavior, manifested as an approximately two-fold reduction in predicted nAb IC50.
https://doi.org/10.1371/journal.ppat.1006313.g004
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per-trimer binding behavior should have a slight neutralization advantage, especially under
conditions of low nAb concentrations.
Estimating the in vivo efficacy of passive nAb immunization and single-
virion infectivity
We next predicted nAb neutralization efficacy and host infection probability in vivo by re-
assessing data from four studies of rhesus macaque vaginal virus challenge following passive
immunization with nAbs b12 [8], 2G12 [7], PGT121 [10] and PGT126 [16]. Our approach
consists of two parts: first, we utilized the nAb neutralization prediction model developed
above (Fig 4) to estimate how many virions of the challenge dose are neutralized in vivo in
dependence on the nAb immunization regime. Secondly, we connected this number of non-
neutralized virions to the number of animals protected or infected for a given immunization
and challenge regime. Ultimately, this allows us to derive the probability for a single infectious
virion to establish a host infection (Fig 5A).
This modelling of HIV-1 neutralization in vivo following vaginal challenge requires data on
vaginal nAb concentrations and nAb KD as well as the virus-specific parameters of inoculum
size, Z, T and N. Importantly, we also require the probability of virions to penetrate mucosal
epithelial layers to come in contact with target cells (ppen); this parameter was recently esti-
mated elegantly by Carias et al. [50]. The four selected macaque studies reported the majority
of nAb and virus-specific parameters (S6 and S7 Tables), allowing us to employ our modelling
approach in a post-hoc analysis. Essential data of the four analyzed studies are listed below:
(i). In the b12 study [8], 5 animals were immunized weekly with 1 mg/kg nAb b12, giving
average serum b12 concentrations of 41.8 μg/ml and extrapolated vaginal mucosal con-
centrations of 0.47 μg/ml (S6 and S7 Tables). Animals were challenged bi-weekly with
virus SHIV-P3, first 11 times with 3 TCID50 (397.500 virions) and subsequently 40
times with 10 TCID50 (1.325.000 virions). One animal was infected after 6 challenges
with 3 TCID50, while 3 animals were infected after 6, 23 and 38 additional challenges
with 10 TCID50, and one animal remained uninfected throughout the challenge
regime.
(ii). In the 2G12 study [7], 5 animals were immunized once with 40 mg/kg nAb 2G12, giv-
ing average serum 2G12 concentrations of 1053 μg/ml and extrapolated vaginal muco-
sal concentrations of 12 μg/ml (S6 and S7 Tables). Animals were challenged once with
500 TCID50 (66.250.000 virions) of virus SHIV-P3. Three animals were protected,
while 2 became infected.
(iii). In the PGT121 study [10], 5 animals per group were immunized once with either 5, 1
or 0.2 mg/kg of nAb PGT121, giving average serum PGT121 concentrations of 95, 15
and 1.8 μg/ml, respectively. Vaginal mucosal concentrations were measured at 0.9 and
0.2 μg/ml for the 5 and 1 mg/kg immunizations and extrapolated at 0.02 μg/ml for the
0.2 mg/kg immunization (S6 and S7 Tables). Animals were challenged once with 300
TCID50 (39.750.000 virions) of virus SHIV-P3. All animals with 5 and 1 mg/kg
PGT121 immunizations were protected, while 3 animals were protected and 2 became
infected for the 0.2 mg/kg immunization.
(iv). In the PGT126 study [16], 5 animals per group were immunized once with either 10, 2
or 0.4 mg/kg of nAb PGT126, giving average serum PGT126 concentrations of 98, 20
and 3.6 μg/ml, respectively. Vaginal mucosal concentrations were extrapolated at 1.1,
0.22 and 0.04 μg/ml for the 10, 2 and 0.4 mg/kg immunizations, respectively (S6 and S7
Predicting HIV-1 antibody neutralization in vivo
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006313 May 4, 2017 11 / 35
Tables). Animals were challenged once with 300 TCID50 (39.750.000 virions) of virus
SHIV-P3. All animals with 10 mg/kg PGT126 immunizations were protected, while 2
animals were protected and 3 became infected for the 2 mg/kg immunization, and 1
animal was protected and 4 became infected for the 0.4 mg/kg immunization.
To derive nAb KD data for the challenge virus Env P3 used in all four studies, we utilized
the known IC50 for 2G12, b12, PGT121 and PGT126 against P3 and inferred the correspond-
ing KD values by linear regression (S6 and S7 Tables). We further assumed that virus strain P3
has T = 2 and Z ¼ 20 as previously determined for the closely related strain P3N (S3 Table).
These data enabled us to predict neutralization curves for the four nAbs against SHIV-P3 (S14
Fig). We then superimposed these nAb neutralization curves with the estimated nAb concen-
trations in the vaginal mucosa at the time of challenge. In this analysis, we allowed both nAb
KD and mucosal nAb concentrations to vary 2-fold around the estimated values to account for
potential inaccuracies in the extrapolation procedures. This analysis yielded windows for the
extent of SHIV-P3 inoculum neutralization by the four nAbs in vivo (S14A Fig, colored parts
of the neutralization curves). We predicted almost complete SHIV-P3 inoculum neutralization
Fig 5. Antibody neutralization and host infection in macaque passive immunization challenge studies. (A) Scheme depicting our
approach of post-hoc analysis of macaque passive nAb immunization vaginal virus challenge studies. The approach delivers both estimates
of in vivo virus inoculum neutralization and the probability of each infectious virion to start a host infection. (B) Total number of SHIV-P3
virions remaining infectious in the four analysed studies, obtained by multiplying the study-specific SHIV-P3 virus inoculum sizes with the
fraction of virions remaining non-neutralized by nAbs. Bars depict the lowest, mean and highest number of potentially infectious virions,
based on different assumptions of nAb KD and mucosal nAb concentration (see S14 Fig). (C) Estimates for the probability that a single
infectious virion starts a host infection,ψ, shown for each of the four individual macaque studies. The different symbols and bars depict the
lowest, mean and highest values ofψ, based on the different estimates for the number of potentially infectious virions as shown in (B). For
this analysis, only immunization and challenge regimes resulting in infection of test animals were considered. The average value ofψ
(1.65x10-5) across all studies is indicated.
https://doi.org/10.1371/journal.ppat.1006313.g005
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for the highest PGT121 and PGT126 immunization regimes, while the b12 and 2G12 immuni-
zations and the low doses of PGT121 and PGT126 immunizations yielded intermediate
SHIV-P3 neutralization levels, mirroring the protective effects seen in the respective challenge
studies [7, 8, 10, 16].
Importantly, our model also allowed us to determine the probability that a single infectious
virion starts a host infection. To this end, we first calculated the fraction of SHIV-P3 virions
that remained potentially infectious in the four macaque challenge studies, i.e. virions with at
least T non-neutralized trimers (S14B Fig). Multiplying these fractions of non-neutralized viri-
ons with the total number of virions in the respective challenge inocula provided an estimate
of the number of virions that remained potentially able to infect each animal (Fig 5B).
To investigate how this number of non-neutralized, infectious virions translates into sys-
temic host infection we utilized a further parameter. During vaginal challenge not all virions of
the inoculum will penetrate the vaginal epithelial layers to come in contact with mucosal CD4+
target cells; the probability of epithelial penetration is given by ppen. We assumed that only
0.235% of virions will penetrate the genital tract epithelium as experimentally estimated [50].
Based on this, we derived the number of infectious virions in the four challenge studies that
can potentially contact mucosal target cells and set these number in relation to the observed
infection outcomes (Fig 5A). This delivered the probability for a single infectious virion to
establish a systemic host infection, denoted ψ (Fig 5C). Intriguingly, we obtained closely
matching ψ-estimates for the four independent macaque studies, with an average value of
c^ ¼ 1:65 10  5.
Next, we asked whether a similar analysis would be possible using in vitro nAb neutraliza-
tion data (i.e., nAb IC50 and Hill parameter). For this analysis we utilized in vitro neutraliza-
tion data of SHIV-P3 with nAbs PGT121, PGT126 and b12 (S11B Fig) and analyzed the
respective macaque challenge studies. We obtained a closely matching estimate of ψ, i.e. c^ ¼
2:95 10  5 (S15 Fig) as with our mechanistic population neutralization model (Fig 5C).
Based on these two complementary analyses, we conclude that only one in ~30.000 to 60.000
infectious virions that have penetrated the vaginal epithelial layers will succeed in systemically
infecting the host. This estimate thereby provides a quantitative evaluation of the bottlenecks
encountered by HIV-1 during transmission in the genital mucosa.
Predicting human infection probabilities and nAb levels required to
protect from HIV-1 acquisition
We next used the estimate of HIV-1 virion host infection probability (c^ ¼ 1:65 10  5) to
predict male to female HIV-1 transmission risk per sex act and nAb protection efficacy. In this
analysis, we define the per-act HIV-1 inoculum as the number of HIV-1 virions per ejaculate;
this number is given by per-ejaculate semen volume and semen viral load. We then assumed
that only a fraction of virions in the inoculum will penetrate the vaginal epithelial layers,
defined by ppen [50]. We next determined the number of virions that are potentially infectious,
i.e. have at least T trimers, and multiplied the fraction of penetrating infectious virions with
the probability for each infectious virion to initiate host infection, ψ. Thus, we obtained the
probability of host infection in dependence on HIV-1 inoculum size. In addition, we modelled
protective effects of nAbs present in the vaginal mucosa; here, the extent of HIV-1 inoculum
neutralization (and hence the magnitude of protection) depends on mucosal nAb concentra-
tion and nAb binding affinity (KD) for the Env trimer.
In a first step, we calculated infection probabilities of women during a single penile-vagi-
nal intercourse in dependence on HIV-1 inoculum size, in absence of nAbs. We performed
this analysis for HIV-1 virions with the entry characteristics of the transmitted-founder
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strain BG505 (Z ¼ 9:5 trimers per virion, T = 2 entry stoichiometry; S3 Table). The resulting
relation between HIV-1 inoculum size and per-act female host infection probabilities is
shown in Fig 6A.
This relation needs to be interpreted with regard to empirical data of human HIV-1 semen
viral loads and per-act transmission risk. In chronic HIV-1 infection, semen viral load typically
ranges between 200 and 20.000 HIV-1 RNA genome copies per mL seminal plasma (i.e.,
100 to 10.000 virions / mL, assuming two viral genomic RNA copies per virion). During acute
infection, semen viral load typically ranges between 20.000 and 200.000 RNA copies / mL
(10.000 to 100.000 virions / mL) [33]. In rare cases, semen viral loads of several million RNA
copies / mL (>1.000.000 virions / mL) were reported [51]. Assuming an average per-ejaculate
semen volume of 3 mL [51, 52], this results in typical HIV-1 inoculum sizes of 300 to 30.000
virions during chronic HIV-1 infection, 30.000 to 300.000 virions during acute infection,
and> 3.000.000 virions in rare cases. The corresponding per-act female infection probabilities
predicted by our model are 0.001 to 0.11% during chronic infection (one in 87.000 to one
in 876 sexual contacts), 0.11 to 1.14% during acute infection (one in 876 to one in 88 sexual
contacts), and maximum values exceeding 11% (one in 9 sexual contacts) (Fig 6A).
How do these estimates compare to empirical data on female per-act infection probabili-
ties? A frequently stated number for male-to-female penile-vaginal transmission risk is 1 in
1000 sexual contacts (0.1%). However, as previously discussed [32, 53, 54], this likely repre-
sents a lower bound of per-act infection risk and may be dangerously misleading. Our model
predicts that an HIV-1 inoculum of ~26.000 virions (i.e., a semen viral load of ~17.000 RNA
copies per mL, assuming 3 mL semen volume) would result in a female per-act infection risk
of 0.1%. This semen viral load lies within the range typically observed during chronic HIV-1
infection. In contrast, several studies reported per-act penile-vaginal female infection risks
between 0.5 and 10%, presumably linked to acute or late-stage HIV-1 infection of the male
partner and correspondingly higher semen viral loads ([32, 53, 54] and references therein).
Indeed, our model predicts HIV-1 inoculums of 130.000 to 2.770.000 virions (semen viral
loads of 87.000 to 1.850.000 HIV-1 RNA copies / mL) to result in per-act infection risks of 0.5
to 10%. These values represent the range of semen viral loads typically observed during acute
Fig 6. Predicting protective antibody levels in vaginal HIV-1 transmission. (A) Model predictions for male to female per-act HIV-1
transmission risk in absence of nAbs and in dependence of HIV-1 inoculum size. The range of typical HIV-1 inoculum sizes in semen
(defined by semen viral load and semen volume) observed in chronic and acute stages of HIV-1 infection and the corresponding predicted
per-act infection risks are indicated in grey shadings. (B) Model predictions for male to female per-act HIV-1 transmission risk in dependence
on vaginal mucosal nAb concentrations. A relatively high HIV-1 inoculum of 100.000 virions was assumed. NAbs with four different KD are
modelled, spanning the range from less potent to very potent nAbs. (C) Model predictions for male to female per-act HIV-1 transmission risk
in dependence on vaginal mucosal nAb concentrations, assuming four different HIV-1 inoculum sizes and a medium-potent nAb.
https://doi.org/10.1371/journal.ppat.1006313.g006
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HIV-1 infection and rare cases of exceedingly high semen viral load. Thus, our model appears
to precisely capture and recapitulate the interplay between HIV-1 inoculum size and infection
probability during HIV-1 transmission in the female genital tract suggested by empirical
studies.
Having thus obtained good indications that our model and the decisive parameter of ψ reli-
ably mirror empirical data of human mucosal HIV-1 transmission, we next aimed to model
the protective effects of nAbs present in the vaginal mucosa. First, we assumed an HIV-1 inoc-
ulum of 100.000 virions and modelled neutralization by four nAbs with a broad range of KD
(Fig 6B). Not surprisingly, this showed that with increasing nAb KD (decreased Env trimer
binding affinity), higher mucosal nAb concentrations are required to provide protection from
infection. Specifically, we found that nAbs with a high Env binding affinity, such as PGT121,
would afford protection from infection well below mucosal nAb concentrations of 0.1 μg/mL.
This suggests that nAbs with high Env binding affinity could exert protective effects in vivo at
relatively low doses.
We next looked more closely at the protective effects of a nAb with intermediate Env affin-
ity and reduced potency, reasoning that such nAbs may be more readily inducible by vaccina-
tion. We chose nAb b12 as an example and modelled its protective effects in the vaginal
mucosa against various HIV-1 inoculum sizes (Fig 6C). This analysis showed that such
medium-potent nAbs may provide considerable protective effects starting in the range of 1 μg/
mL mucosal nAb concentration.
In summary, the analyses shown in Fig 6 suggest that our model has the potential to retrieve
information relevant to human mucosal HIV-1 transmission, offering opportunities for fur-
ther model extension and application in HIV-1 vaccine research (Fig 7).
Discussion
Broadly neutralizing antibodies are considered a crucial component of many vaccines or infec-
tious disease therapeutics. For HIV-1, defining the best lead antibodies has proven complex
Fig 7. Modelling HIV-1 mucosal transmission and antibody neutralization. Summary of the parameters incorporated into our model
(left), allowing in silico analysis of host HIV-1 infection probabilities and the in vivo protective effects of neutralizing antibodies (right).
Parameters shown in red were estimated in this study, while parameters shown in black were retrieved from the literature. The model
framework can be expanded by a range of parameters to investigate additional factors involved in HIV-1 transmission and prevention
(bottom), and may serve as blueprint for similar efforts in other viral disease settings or mucosal infection processes.
https://doi.org/10.1371/journal.ppat.1006313.g007
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and affords intensive in vitro and in vivo efficacy testing in both animal models and humans.
Thus, in silico modelling approaches that support such trials would be of enormous value;
however, establishment of such models depends on detailed mechanistic knowledge of HIV-1
transmission and nAb neutralization processes. Here, we provide a step towards this by pre-
senting an experimental and mathematical analysis of HIV-1 nAb neutralization spanning
from the molecular to the organismal level, providing highly relevant quantitative insights into
the initial steps of mucosal HIV-1 infection and its inhibition by nAbs.
We first assessed the molecular interplay between nAbs and the HIV-1 Env trimer and con-
firmed that nAb occupancy of one Env subunit is sufficient for trimer neutralization (N = 1).
It is important to note that N refers to the number of subunits within one trimer required to
be nAb-bound for loss of functionality. This definition does not exclude the possibility that
one nAb binds two adjacent trimers on the virion surface, which would result in lower nAb
concentrations required for virion population neutralization.
N = 1 proved true for all nAbs tested here, irrespective of epitope specificity or nAb breadth
and potency, including weakly neutralizing polycloncal IgG in HIV-1+ patient plasma (Figs 2
and 3). This indicates that the intricate machinery of the HIV-1 Env trimer, required to medi-
ate binding to and fusion with the target cell membrane, is dependent on full functionality of
all three trimer subunits. By confirming that HIV-1 neutralization follows an N = 1 stoichiom-
etry, we defined a decisive numerical requirement for HIV-1 virion neutralization by nAbs.
Indeed, in combination with the mean number of trimers per virion (Z) and the number of tri-
mers required for entry (T), N defines the threshold number of antibodies required to neutral-
ize a single HIV-1 virion or entire virion populations [27].
Alongside a range of additional parameters that were only recently determined (Fig 1), the
estimation of N enabled us to use a mathematical model to analyze the interplay between
nAbs, HIV-1 virion populations and the animal or human host during HIV-1 infection. We
demonstrate the power of this model through several analyses. First, we predicted IC50 values
of various nAbs and found that the predicted values closely matched empirical IC50 values
(Fig 4). Next, we analyzed published data of macaque passive antibody immunization, vaginal
virus challenge studies (Fig 5). We utilized the data presented in these studies to recapitulate
virus inoculum neutralization by nAbs in vivo and to estimate the probability that a single
infectious virion starts a productive host infection (c^ ¼ 1:65 10  5).
In a final set of analyses, we applied the estimate of ψ to model HIV-1 infection in the female
genital tract and its neutralization by nAbs (Fig 6). We found that the per-act likelihood of
female HIV-1 infection is clearly driven by the size of the virus inoculum, and we retrieved per-
act virus transmission probabilities in good agreement with empirical estimates [32, 33, 51, 53].
Furthermore, we provide estimates for mucosal nAb concentrations required to provide protec-
tion from infection, indicating that nAb concentrations in the low μg/ml range may provide
protection from mucosal HIV-1 transmission. Similar concentrations of HIV-1-specific IgG are
readily detectable in the vaginal mucosa of women with chronic HIV-1 infection, raising the
possibility that such vaginal IgG concentrations may be achievable by vaccination [55].
The analyses of female infection risk shown in Fig 6 represent the synthesis of all previous
analyses (Figs 2 to 5), incorporating all modelling parameters (Figs 1C and 7). It will remain
difficult if not impossible to precisely determine per-act HIV-1 inoculum sizes and infection
outcomes in a human study population as well as the effect of nAbs thereon. The data we
obtained here suggests that our mathematical framework has the potential to retrieve some of
this much needed information by in silico modelling of in vivo HIV-1 infection and nAb neu-
tralization. Given this potential relevance, in the following we discuss these estimates and the
underlying model assumptions in more detail.
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First, our model framework was built on data from macaque vaginal challenge studies.
While host differences certainly exist, basic principles of mucosal HIV transmission in
macaques and humans are similar [56, 57]. Penetration of mucosal barriers has been shown in
both cases to be a rapid but inefficient process resulting in focal infection of few mucosal
CD4+ cells, with productive host infection frequently ensuing from a single transmitted-
founder virus [50, 58–60]. The probabilities we derive here for virion infectivity in macaque
vaginal mucosal transmission should thus provide valuable insight into human infection
processes.
Secondly, we would like to point out the importance of patient-to-patient variation, espe-
cially for the relation between HIV-1 inoculum size and host infection probability (Fig 6A). Of
note, the per-patient and per-act HIV-1 inoculum size may differ widely based on variation in
semen viral load and semen volume, which may both range over several orders of magnitude
[33, 51, 52, 61, 62]. Our analyses support the hypothesis that HIV-1 transmission probability
from an infected male partner with semen viral loads as typically observed in the chronic stage
of HIV-1 infection is relatively low ( 0.1%), and that the HIV-1 pandemic may be primarily
driven by transmissions occurring through high semen viral loads during acute or late-stage
infections [33, 63].
Third, we focused our analysis on male to female HIV-1 infection, as it represents the most
frequent pathway of human HIV-1 transmission [64]. However, our model is not per se limited
to the setting of penile-vaginal transmission and can be adapted to capture rectal, mother-to-
child or intravenous HIV-1 transmission. For example, many recent non-human primate
studies tested passive nAb immunization followed by rectal virus challenge [11–13, 16, 18, 19].
The data presented in these studies could be leveraged by our model framework, as demon-
strated here for vaginal challenge, to estimate ψ for rectal infection and subsequently test
hypotheses for rectal HIV-1 transmission risk.
Fourth, mucosal nAb levels are challenging to measure and were not available in all
macaque challenge experiments analysed here. Thus, we extrapolated mucosal nAb concentra-
tions based on blood plasma nAb levels, using the ratio between plasma and mucosal nAb con-
centrations from studies where both parameters were experimentally determined. While this
provided valuable estimates, precise measurement of mucosal nAb levels would be ideal for
future studies building on our model framework.
Overall, we would like to note that our model should be viewed as a starting point to further
investigate in vivo HIV-1 infection and nAb neutralization processes, as it focuses solely on
virus-antibody interactions leaving additional factors, such as the mucosal milieu and nAb
effector functions, not accounted for. The model can and should be fine-tuned by incorpo-
ration of additional parameters once they become known (Fig 7). Mucosal HIV-1 infection is
incompletely understood and bottlenecks in transmission that may specifically select viral vari-
ants have not been specified. It remains debated whether HIV-1 transmitted-founder strains
show distinct properties or whether transmission is purely stochastic [65–68]; our approach
may help to shed light on this important question. Additionally, a range of factors are consid-
ered to influence mucosal HIV-1 transmission including epithelial micro-trauma, local inflam-
mation, presence of other sexually transmitted infections, mucosal target cell availability, and
innate immune defences [24, 69–71]. Reliably parametrizing these conditions will remain chal-
lenging but could add valuable information in forthcoming studies utilizing our model frame-
work. Furthermore, our model currently does not include selected nAb features that may
impact on neutralization efficacy, including the effect of neutralization plateaus [13, 49, 72],
the contribution of Fc-mediated mechanisms [73–75], the effect of non-neutralizing Abs [76–
79] and the role of IgA in HIV-1 inhibition [80–82]. Most importantly with respect to neutrali-
zation efficacy, information on nAb half-life and tissue distribution is only starting to emerge
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[83, 84]. In combination, these factors likely contribute substantially to inter-patient variation
in susceptibility to HIV-1 infection, and it will be highly interesting to incorporate them in
future model extensions.
By estimating the probability that an infectious HIV-1 virion establishes an infection (ψ),
and by being able to predict the effect of mucosal nAbs on HIV-1 infection risk, our study
occupies a sweet spot between HIV-1 mathematical epidemiology and virus dynamics studies.
Modelling studies of the epidemiological spread of HIV-1 [85–87], on the one hand, are typi-
cally not accounting for the transmitted virus dose, but rather assume a fixed probability of
transmission between donor and recipient upon encounter. While the probability of transmis-
sion is often stratified by cofactors (such as sex or age of donor or recipient, or set-point viral
load in the donor) it lacks the detailed mechanistic underpinning that our approach provides.
Virus dynamics studies of HIV-1, on the other hand, are mostly concerned with the virus
dynamics once the infection has been established, often focusing on changes brought about by
treatment [88, 89]. In these studies, the anatomy of the host is usually not considered in detail.
The necessity of integrating the within-host dynamics into the epidemiological modelling of
any pathogen has been theoretically conceived [90, 91]. In the context of HIV-1, however,
such so-called nested or embedded approaches have so far been used only in theoretical studies
on the evolutionary dynamics of HIV-1 [92–94]. In a few studies, the probability of establish-
ment of an infection along with its potential modulators, such as microbicides, T cells, expo-
sure history, or latency, has been investigated for HIV-1 and SIV [95–101] as well as for other
pathogens [102]. However, these studies did not provide the bottom-up empirical link between
the establishment of an infection and mucosal antibody levels that is central to our approach.
A notable exception is the study by McKinley et al. [103] who presented a model for the early
virus dynamics and the effect of antibodies. In contrast to our model, however, they predict
neutralization success purely on the basis of the binding kinetics (KD) of antibodies to the
HIV-1 Env trimer. In summary, our study thus provides a comprehensive set of essential and
empirically-derived parameters for modelling efforts that aim to combine the within and
between host dynamics of HIV-1 infection.
In conclusion, our combined experimental-mathematical approach delivers precise esti-
mates of virion-antibody interaction stoichiometry, single-virion mucosal transmission proba-
bility, male to female per-act infection risk and in vivo nAb neutralization efficacy. These data
represent novel quantitative insight into both the molecular details of HIV-1 antibody neutral-
ization and the systemic level of mucosal HIV-1 infection. Our findings suggest that the model
framework introduced here incorporates essential parameters that capture decisive steps of
early HIV-1 infection and nAb neutralization, and thus provides means to predict and analyse
the effects of nAbs on blocking mucosal virus transmission in vivo. Furthermore, our frame-
work offers vast options for model extensions to investigate additional parameters or entirely
different infection scenarios (Fig 7). Thus, our work represents a versatile, generalizable
modelling tool to enhance our fundamental mechanistic knowledge of virus-antibody interac-
tions and viral mucosal transmission, and can serve as stepping stone for planning and post-
hoc evaluation of HIV-1 antibody-based treatment and vaccine trials.
Materials and methods
Ethics statement
Plasma samples from chronically infected individuals (ZA110, Pat117, Pat118, Pat122) were
obtained from biobank samples previously collected during two approved clinical trials, the
Swiss treatment interruption trial [104–108] and the Zurich Primary HIV-infection (ZPHI)
study (ClinicalTrials.gov identifier NCT00537966) [109]. Written informed consent was
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obtained from all individuals in the respective studies according to the guidelines of the ethics
committee of the canton Zurich.
Cells and Env variants
293-T cells (obtained from the American Type Culture Collection) and TZM-bl cells [110]
(obtained from the NIH AIDS Reagent Program) were cultured as described [111]. The origin
of HIV Env plasmids is listed in S3 Table. Env point mutations were generated by site-directed
mutagenesis (Agilent QuikChange II XL kit). All Env mutants were confirmed by sequencing.
V1V2-deleted Envs were previously described [44]. The Luciferase reporter HIV-1 pseudotyp-
ing vector pNLLuc-AM was previously described [111].
Reagents
MAbs (see S4 Table) were kindly provided by: PG9, PGT121, PGT128, PGT135, PGT145, b12
and b6 by Dr. Dennis Burton, The Scripps Research Institute, La Jolla, USA. 2F5 and 2G12 by
Dr. Dietmar Katinger, Polymun Scientific, Vienna, Austria. 17b and 48D by Dr. James Robin-
son, Tulane University, New Orleans, USA. 447-52D was purchased from Polymun Scientific.
Expression plasmids for VRC01 and PGV04 were provided by Dr. John Mascola, National
Institutes of Allergy and Infectious Diseases, Bethesda, USA. Expression plasmids for
NIH45.46 and 1.79 were provided by Dr. Michel Nussenzweig, The Rockefeller University,
New York, USA. T-20 was purchased from Roche Pharmaceuticals.
Estimating the stoichiometry of neutralization, N, with mixed trimer
assays
To produce HIV-1 pseudovirus stocks expressing mixed trimers with varying ratios of nAb-
sensitive to nAb-resistant Env, 293-T cells in 6-well plates (250.000 cells per well in 2 ml com-
plete DMEM, seeded 24 h pre-transfection) were transfected with 3 μg pNLLuc-AM and 1 μg
Env expression plasmids, using polyethyleneimine (PEI) as transfection reagent. The ratio of
sensitive to resistant Env was varied to yield combinations with 100, 90, 70, 50, 30, 10 and 0%
of resistant Env. After overnight incubation the transfection medium was replaced with 2.5 ml
fresh complete DMEM and virus-containing supernatants were harvested 48 h post transfec-
tion. To determine virus infectivity, serial dilutions of virus stocks were added to TZM-bl cells
in 96-well plates (10.000 cells per well) in DMEM supplemented with 10 μg/ml DEAE-Dex-
tran. TZM-bl infection was quantified 48 h post-infection by measuring activity of the firefly
luciferase reporter (in arbitrary relative light units, RLU). The neutralization activity of mAbs
and patient plasma against the mixed trimer virus stocks was evaluated on TZM-bl cells as
described [111]. Sufficiently high starting concentrations of inhibitors were chosen to yield
clear neutralization plateaus, and data were fitted in GraphPad Prism version 7.0 using the sig-
moidal dose-response (variable slope) function. In cases where no clear neutralization plateaus
were obtained (less than two consecutive data points giving the same level of neutralization),
the position of the expected plateau was provided by the curve fit. Subsequently, the relative
infectivity (RI) of each virus stock under saturating inhibitor concentrations was calculated.
The resulting RI values were plotted over the fraction of resistant Env (fR) of each virus stock
and the data were analyzed with mathematical models.
Env expression analysis by flow cytometry
293-T cells were transfected with Env and Rev plasmids and processed for flow cytometry as
described [37]. Env on the cell surface was detected with biotinylated mAb 2G12 (5 μg/ml)
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and Streptavidin-APC (BioLegend, San Diego, USA; 1:400 dilution) or Abs 1.79 and PG9
(5 μg/ml) and Cy5-conjugated F(ab0)2 goat anti–human IgG (Jackson ImmunoResearch, West
Grove, USA; 1:500 dilution) followed by cell analysis on a CyAN ADP flow cytometer (Beck-
man Coulter, Brea, USA).
Mathematical modeling to estimate N and HIV-1 population
neutralization
Trimer neutralization model. The trimer neutralization model is used to determine the
stoichiometry of neutralization, N. This model was described in detail in Magnus and
Regoes, 2010 [26]. Briefly, it predicts relative virus infectivity as a function of trimer compo-
sition. The model factors in the number of trimers needed for virus entry (the entry stoichi-
ometry, T) and the distribution of trimer numbers across the virion population, η. Trimer
assembly is modeled by randomly choosing three Env subunits from a subunit pool consist-
ing of nAb-sensitive and nAb-resistant Envs (according to a binomial distribution). The
fraction of nAb-resistant Env subunits is denoted by Z. As extensive determination of the tri-
mer number distribution, η, is lacking, we use a discretized Beta distributed trimer number
distribution with mean Z and variance 49/14 Z according to Magnus et al., 2009 [25] and
Zhu et al., 2006 [112].
Thus, the relative infectivity (RI) is given by
RIN ¼
Xsmax
s¼T
Zsð
Xs
g¼T
ð
s
gÞa
g
Nð1   aNÞ
s  g
Þ
Xsmax
s¼T
Zs
where smax = 100 is the maximal number of trimers per virion and aN ¼
X3
m¼ð3  NÞþ1
ð
3
mÞf
m
R ð1   fRÞ
3  m
is the probability that a trimer is functional, i.e. non-neutralized by
nAb, which depends on N.
For estimating N, we use virus strain-specific estimates of T and Z determined in Branden-
berg et al., 2015 [28]. Note that virions with less than T trimers are considered as non-infec-
tious. For example, assuming a mean trimer number of Z ¼ 11:8 and a variance of 41.3, only
99.36% of all virions are infectious if T = 2, respectively 78.23% for T = 7 (S16A Fig). Broader
trimer number distributions, i.e. distributions with higher variance, result in lower fractions of
infectious virions (S16B Fig). These numbers are not equal to the infectious to non-infectious
virion ratios, which are normally much smaller. The reason for this is that in the infectious to
non-infectious ratio one usually compares the virions actually infecting a cell to those that do
not. In our model we approximate this by summing over the infectious virions given a certain
fraction of mutated Envs and by subsequently dividing this by the infectious virions of a
completely nAb-susceptible virus strain (see the RI-equation above).
Note that N is defined as the minimal number of trimer subunits required to be bound to
an antibody such that the trimer loses functionality. Following this definition, N can only take
the values 1, 2 or 3. In so-called soft threshold models [26, 29], binding of each antibody incre-
mentally reduces the probability of the trimer to take part in infection. These models can
potentially be interpreted as N<1. To test the soft threshold model, we use the same methods
on our RI data sets as previously described in [26].
In addition to the above-described model, we developed a model in which a trimer has
three potential epitopes of which only one can be bound by an antibody. Binding of the first
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antibody disallows further antibody binding. This model reflects the binding behavior of PG9
and PGT145-like antibodies that are known to only bind with one antibody per trimer.
The RI curve is fitted to the experimental data with a nonlinear regression method (residual
sum of squares, rss) and the estimate of N is the N-value for which the rss is the lowest. In addi-
tion, we performed a bootstrap procedure with 1000 replicates to determine the confidence/
reliability of the N estimates. All estimates have a confidence of at least 95%. For a sensitivity
analysis we estimate N for different T’s ranging from 1 to 20 and the mean number of trimers
Z ranging between 5 and 25 (see S4 Fig). Given the experimentally determined T and Z values
[28], our estimates for N are those with the lowest rss-values. If we leave Z and T free, however,
the minimal rss values would be reached for a combination of lower mean virion trimer num-
bers Z in combination with higher stoichiometries of entry, T (see Fig 2E).
Population neutralization model
(i). NAb concentrations that confer sterilizing immunity
To tackle the question how high nAb concentrations must be to neutralize a given virion popu-
lation, we first study the number of nAbs required to perform this task. We start with a virus
population with nv virions. Each virion has a random trimer number Si that follows a discre-
tized Beta distribution with mean Z and variance v ¼ 49=14 Z (see above). We let nAbs
bind to these virions until all virions are neutralized. Neutralization of virion i is achieved
when at least (Si − T + 1) trimers are bound to at least N nAbs. This simulation is repeated nr =
1000 times and the mean of the nAb numbers to reach neutralization is calculated. We intro-
duced this procedure in Magnus and Regoes, 2011 [27].
To transition from nAb numbers required for virion neutralization to nAb concentrations,
we model the binding of a nAb, Ab, to an envelope protein, E, with a chemical binding equa-
tion [35]:
E þ AbÐ
ka
kd
EAb
where kd is the off-rate constant and ka the on-rate constant. Assuming a first order reaction,
the quotient of the product of the reactant concentrations divided by the product concentra-
tion follows:
KD≔
kd
ka
¼
cðEÞcðAbÞ
cðEAbÞ
The fraction of bound envelope proteins, fb, when the equilibrium is reached can then be
calculated by
fb ¼
cðEAbÞ
cðEÞ þ cðEAbÞ
¼ ð
cðEÞ
cðEAbÞ
þ 1Þ
  1
¼ ð
KD
cðAbÞ
þ 1Þ
  1
This equation can be transformed to
cðAbÞ ¼
KDfb
1   fb
With this equation it is possible to determine the nAb concentrations needed for sterilizing
neutralization by determining the fraction of bound envelope proteins with the simulation
tool described above.
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(ii). Calculating the neutralization levels for different nAb concentrations
We start with calculating the percentage of neutralized virions when nAb nAbs are bound to
nv virions. Each virion has a discretized Beta distributed trimer number, Si, with mean Z and
variance v ¼ 49=14 Z. We then distribute the nAb nAbs to the virions such that each enve-
lope protein has the same probability of being bound. Thus Ai nAbs bind to virion i.
The probability that a virion with s trimers is neutralized when a nAbs bind to the complete
virion can be calculated as follows:
PðneutjS ¼ s;A ¼ aÞ ¼ 0 if a < ðs   T þ 1ÞN;
PðneutjS ¼ s;A ¼ aÞ ¼ 1 if a  3ðs   TÞ þ ðN   1ÞT þ 1
and
PðneutjS ¼ s;A ¼ aÞ ¼
X
ðy1 ; y2 ;y3Þ2εa;s
PðY1 ¼ y1; Y2 ¼ y2; Y3 ¼ y3Þ
where P(Y1 = y1, Y2 = y2, Y3 = y3) is the probability that yj trimers are bound to j nAbs and ℇa, s
is the set of all combinations of a nAbs to s trimers such that at least (s − T + 1) trimers are
bound to at least N nAbs. For N = 1 this set is
εa;s ¼ ððy1; y2; y3Þ 2 N
3
0
jy1 ¼ m; y2 ¼ 3z   a   2m; y3 ¼ aþm   2z
with 0  m  minðs;aÞ and s   T þ 1  z  sÞ
The fraction of neutralized virions, fnv , can thus be calculated by:
fnv ¼
1
nv
Xnv
i¼1
PðneutjSi ¼ si;Ai ¼ aiÞ
To calculate the mean fraction of neutralized virions, the above described procedure is per-
formed nr = 1000 times.
Several nAbs have been shown to bind with only one antibody per trimer, including nAbs
PG9, PG16 and PGT145 [38, 47, 49]. To account for this binding behavior, we extended the
above described model. We still assume that each trimer has three epitopes. However, as soon
as one nAb binds to a trimer, no additional nAbs can bind. The fraction of bound epitopes is
then fb, epitopes = 1/3fb, trimers and a virion with s trimers is neutralized when (s − T + 1) trimers
are bound by one nAb.
In vivo protection model. Here, we use the above described model to predict virus neu-
tralization levels in macaque passive nAb immunization, vaginal challenge studies [7, 8, 10,
16]. In Fig 5, we show neutralization curves predicted with the above described models based
on estimated nAb KD values for the P3 challenge virus. The results are based on simulations
with nv = 1000 virions.
Determining the probability that an infectious virion starts a host infection. How high
is the probability, here denoted ψ, that an infectious virion starts a host infection? This proba-
bility is modeled to be independent of the number of antibodies bound as long as the virion is
still infectious (i.e., has at least T functional trimers). With our stoichiometric framework and
the results from the macaque challenge studies we can approach this question. To this end, we
derive a mathematical expression for the probability that infection happens given a certain
HIV-1 inoculum size. We denote the number of virions forming the inoculum by n. Only viri-
ons that have penetrated the epithelial layer (happening with probability ppen), are not
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neutralized by antibodies (happening with probability 1 − fneut) and have at least T trimers on
their surface (happening with probability
Xsmax
k¼T
Zk) can end up productively infecting the host.
Thus, the effective inoculum size, v, is:
v ¼ nppenð1   fneutÞ
Xsmax
k¼T
Zk
Let Yi, i = 1,. . .,v, be independent, identically distributed random variables with Yi = 1 in
case the ith virion starts the infection and 0 else. The probability that a host infection starts is
then
p ¼ 1   Pð8i¼1;...;v Yi ¼ 0Þ
¼ 1  
Yv
i¼1
PðYi ¼ 0Þ
¼ 1   PðY1 ¼ 0Þ
v
¼ 1   ð1   PðY1 ¼ 1ÞÞ
v
As ψ = P(Y1 = 1) we can use the probability that an infection starts upon challenge, π, to
estimate this parameter. To this end, we use the outcomes of the macaque challenge studies.
However, the two types of challenges–repeated low dose versus single high dose–must be
treated separately: (i) In single high dose challenge studies [7, 10, 16], the outcome of how
many animals are infected follows a binomial distribution. (ii) In repeated low dose challenge
studies [8], the number of challenges required to infect follows a geometric distribution.
(i) Single high dose challenge studies: We denote the number of animals included in a study
with m. The number of infected animals, Z, follows a binomial distribution with infection
probability π, i.e.
PðZ ¼ kÞ ¼ ðmk Þp
kð1   pÞ
m  k
With π = 1 −(1−ψ)v one can easily show that the maximum likelihood estimator for ψ is
c^ ¼ 1   ð1  
k
m
Þ
1=v
(ii) Repeated low dose challenge study: In the low dose challenge study, the animals were first
challenged with an inoculum of n1 = 397500 virions 11 times successively. The animals that
were not infected in this phase were then successively challenged with n2 = 1325000 virions.
The number of infectious virions in phase 1, v1, and in phase 2, v2, can be calculated by tak-
ing into account the penetration probability, ppen, the fraction of neutralized virions, fneut,
and the probability of being infectious. Thus,
v1 ¼ n1ppenð1   fneutÞ
Xsmax
k¼T
Zk
v2 ¼ n2ppenð1   fneutÞ
Xsmax
k¼T
Zk
Predicting HIV-1 antibody neutralization in vivo
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006313 May 4, 2017 23 / 35
We define ψ as the probability that one infectious virion starts a host infection. The proba-
bility that an infection is started upon one challenge in phase 1, π1, and in phase 2, π2, is then
p1 ¼ 1   ð1   cÞ
v1
p2 ¼ 1   ð1   cÞ
v2
For the likelihood function, L(ψ), describing the entire low dose challenge experiment, we
need to factor in all geometrical distributed waiting times for each animal. One animal was
infected after six challenges with viral load n1. Four animals were challenged eleven times with
viral load n1 but remained uninfected. They were then challenged with viral load n2. Three ani-
mals got infected after 6, 23, and 28 challenges with viral load n2. One animal remained unin-
fected even after 40 challenges with viral load n2. Thus:
LðcÞ ¼ ð1   p1Þ
5
p1
ð1   p1Þ
11
ð1   p2Þ
5
p2
ð1   p1Þ
11
ð1   p2Þ
22
p2
ð1   p1Þ
11
ð1   p2Þ
37
p2
ð1   p1Þ
11
ð1   p2Þ
40
¼ p1p
3
2
ð1   p1Þ
49
ð1   p2Þ
104
This function cannot be solved analytically in respect to ψ. We determine the maximum of
the likelihood function numerically.
Estimating ψ. We used the above derived estimators to determine the probability that an
infectious virion starts a host infection, ψ, based on the four macaque challenge studies [7, 8,
10, 16]. Due to the lack of KD measurements for the binding of nAbs b12, 2G12, PGT121 and
PGT126 to the challenge Env P3, we estimated these values based on the respective IC50 and
the correlation between IC50 and KD as demonstrated for BG505 (Fig 4, S6 and S7 Tables).
Specifically, we calculated nAb IC50 values for different KD values assuming a P3-specific tri-
mer number distribution and entry stoichiometry. We then calculated the regression slope
parameter between IC50 and KD values and used this to extrapolate KD values from measured
IC50 values for the nAbs used in the macaque challenge studies.
In addition, the mucosal nAb concentrations were also extrapolated (S7 Table). Therefore,
we estimated ψ for the extrapolated KD and mucosal nAb concentrations and introduced a
2-fold variation of these parameters to account for the extrapolation procedure (Fig 5).
To probe whether it is sufficient to use in vitro nAb neutralization data to estimate ψ, we
used the Hill-curve parameters to calculate the fraction of neutralized virions as a function of
the antibody concentration fneut ¼ cmAb=ðc
m
Ab þ IC50
mÞ and plugged this into the equations for v1
and v2 above.
Predicting protecting antibody levels against HIV-1 infection. Using the estimated
probability that an infectious virion starts a host infection, ψ, it is possible to predict the per-
challenge infection probability as a function of the vaginal mucosal nAb concentration. The
inoculum size in penile-vaginal transmission is the product of semen volume and the semen
viral load. We directly calculate the probability of female infection upon one challenge with a
fixed inoculum of size n. Following the notation in this paper, T is the stoichiometry of virus
entry and Z the virion trimer number distribution. The fraction of neutralized virions, fneut,
depending on the nAb concentration is determined as described above. The probability that
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one challenge with an HIV-1 inoculum of size n leads to infection is thus:
Pðinfection upon exposureÞ ¼ 1   ð1   cÞv ¼ 1   ð1   cÞ
nppenð1  fneutÞ
Xsmax
k¼T
Zk
In this equation, v is the number of virions of the inoculum that penetrated the epithelium,
were not neutralized by nAbs and have sufficient trimers to potentially infect a host cell.
Supporting information
S1 Fig. Verification of Env antibody escape mutants. Our approach to estimate N relies on
Env variants that are resistant or sensitive against neutralization by a given antibody (Fig 2A).
Shown here are neutralization assays on TZM-bl cells with pseudotyped HIV-1 stocks carrying
either wildtype (wt) or nAb escape or sensitivity mutant Envs as listed in S2 Table. Env variants
and inhibitors tested are indicated above each panel. Only mutants showing complete escape
from neutralization by the nAb of interest, or substantial loss in neutralization (<10% neutrali-
zation at a nAb concentration that results in 100% neutralization of the sensitive Env) were
selected for further studies and are shown here. Data depict mean and SD from 2 independent
experiments.
(PDF)
S2 Fig. Influence of T and Z on estimation of N with mixed trimer assays. (A) Model predic-
tions for the influence of Z on RI curve fits. (B) Mixed trimer assays with JR-FL wt (Z ¼ 11:8)
and JR-FL ΔCT (Z ¼ 19:4) and nAb 2F5. The observed RI curve shifts are in agreement with
shifts predicted by our model. (C) Data analysis revealed N = 1 for JR-FL ΔCT and nAb 2F5.
(D) Model predictions for the influence of T on RI curve fits, assuming N = 1. (E) Mixed tri-
mer assays with Envs JR-FL (T = 2) and NL4-3 (T = 7) and nAb 2F5. The observed RI curve
shifts are in agreement with shifts predicted by our model. (F) Data analysis indicated N = 1
for NL4-3 and nAb 2F5. (G) and (H) To test the effect of mono versus bivalent nAb binding
we compared 2F5 IgG and Fab fragment on strains JR-FL and NL4-3. Identical RI profiles for
IgG and Fab fragments were observed. (I) Analysis of the JR-FL and NL4-3 2F5 Fab data indi-
cated N = 1 in both cases.
(PDF)
S3 Fig. Influence of Env infectivity on mixed trimer pseudovirus neutralization assays. (A)
Virus infectivity of JR-FL wt and indicated Env mutants, relative to JR-FL wt. D664N is a nAb
2F5 resistance mutation. (B) Ratio assays with nAb 2F5 and different combinations of JR-FL
mixed trimer pseudovirus stocks. Combining JR-FL wt with JR-FL D664N, which have equal
infectivity, yields a sigmoidal RI profile with an estimated N = 1 neutralization stoichiometry
(Fig 2B and 2C). When the resistant Env (JR-FL D664N) is much more infectious than the sen-
sitive Env (JR-FL ΔV1V2), the RI curve shifts strongly to the left (red squares). When the resis-
tant Env (JR-FL ΔV1V2 D664N) is much less infectious than the sensitive Env (JR-FL wt), the
RI curve shifts strongly to the right (blue triangles). We observed the same effects for HIV-1
strain NL4-3 (C and D). Thus, we only employed sensitive-resistant Env combinations with
similar infectivities (within a two-fold range) for mathematical estimations of N. Interestingly,
Env infectivity differences are not necessarily caused by expression differences (E and F).
Expression of Envs on transfected 293-T cells was assessed by flow cytometry. (E) 293-T cells
were transfected with the indicated ratios of JR-CSF wt and JR-CSF N160K, the latter being
resistant to nAb PG9 and showing only 8% of JR-CSF wt infectivity (S2 Table). Both Envs are
bound (and neutralized) equally well by nAb 2G12. The transfected 293-T cells were stained
with both nAbs PG9 and 2G12 and analyzed by flow cytometry; the mean fluorescence
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intensity of each cell population in relation to cells expressing JR-CSF wt Env only are shown.
Both Envs express to equal levels as judged by 2G12 staining. In addition, we observed a linear
relation of nAb PG9 binding to cells in dependence on the ratio between PG9-sensitive and
resistant Env, as expected. Thus, the low infectivity of JR-CSF N160K is not due to expression
defects. (F) Identical analysis as in (E) for JR-FL wt and JR-FL ΔV1V2, the latter being highly
neutralization sensitive and showing only 4% of JR-FL wt infectivity (panel A, S2 Table).
Again, we observed equal expression levels of the two Envs as judged by 2G12 binding and a
linear binding pattern for the V3 loop directed nAb 1.79, which potently neutralizes JR-FL
ΔV1V2 but not JR-FL wt.
(PDF)
S4 Fig. Robustness analyses of N estimates against variation in T and Z. Shown are robust-
ness analyses for the estimations of N shown in Fig 3A–3G. Each plot depicts the T and Z val-
ues assumed for the analysis of each individual Env combination (white dots; two dots are
shown in case of divergent estimates of T for a given Env, see S3 Table). The resulting estimates
of N in dependence of T and Z are color-coded: blue represents estimates of N = 1, green indi-
cates estimates of N = 2, and red indicates estimates of N = 3. As shown, all N estimates are
clearly within the N = 1 range.
(PDF)
S5 Fig. Bootstrap analyses for estimating N. Bootstrap analysis with 1000 replicates of all
data shown in Fig 3, indicating that the N = 1 estimate is accurate.
(PDF)
S6 Fig. Goodness-of-fit plots for estimating N. Goodness-of-fit analyses of all data shown in
Fig 3. As shown in Fig 2E, better fits would, in most cases, be obtained for lower values of T
and Z.
(PDF)
S7 Fig. Analysis of the RI data (Figs 2 and 3) employing a soft threshold model. This model
extension allows for partial trimer functionality loss upon antibody binding: the functionality
of a trimer with one subunit bound to an antibody is π1, the functionality of a trimer with two
bound subunits is π2, and a trimer with three subunits completely loses its functionality. In
addition, the ability of a virion to infect a cell scales with the number of functional trimers, g,
according to the equation gh/(gh +T1/2h). (A) Estimates of trimer functionality upon antibody
binding. For most virus-nAb combinations, the trimer loses functionality upon binding of one
antibody. (B) Estimates for the steepness of the infection curve, h, and (C) estimates for the
half maximal trimer number, T1/2. A bootstrap procedure shows very high uncertainty in these
point estimates. We therefore discarded this model extension in favor of a “hard” threshold
model.
(PDF)
S8 Fig. Analysis of N on mixed trimer HIV-1 pseudovirus stocks with multiple nAb escape
mutations. (A) to (C): Envs with multiple nAb resistance mutations allowed parallel assess-
ment of various nAbs on the same set of mixed trimer virus stocks. The employed resistant
and sensitive Envs and nAbs tested are indicated above each panel. The three mixed trimer set-
ups shown here were not infectivity-matched, excluding mathematical estimation of N. How-
ever, inclusion of nAb 2F5, previously shown to neutralize with N = 1 (Fig 2), and graphic
comparison of all RI curves indicates equal N (N = 1) of all nAbs tested.
(PDF)
Predicting HIV-1 antibody neutralization in vivo
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006313 May 4, 2017 26 / 35
S9 Fig. Estimating N for the HIV-1 fusion inhibitor T-20. We utilized Env mixed trimer set-
ups that allowed parallel assessment of both nAbs and the HIV-1 fusion inhibitor T-20 to
obtain a direct comparison of the two inhibitor types. (A) Mixed trimer setup with Env
mutants SF162 D279A and V549M N554D and nAbs NIH45.46, PGV04 and entry inhibitor
T-20, indicating equal neutralization stoichiometry of N = 1. Note that in this setup the two
Envs are reciprocally neutralization sensitive and resistant: SF162 D279A is resistant to nAbs
PGV04 and NIH45.46 but sensitive to T-20; the opposite is true for SF162 V549M N554D. (B)
Mixed trimer setup with Env mutants ZA110 ΔV1V2 and V549M N554D and nAbs b6, 447-
52D and PGT145 and entry inhibitor T-20, indicating equal neutralization stoichiometry of
N = 1. All graphs depict mean and SD from 2 independent experiments.
(PDF)
S10 Fig. Predicting antibody concentrations required for sterilizing neutralization of HIV-
1 virion populations. (A) to (C) Predicted nAb concentrations required to completely neutral-
ize HIV-1 virion populations as a function of varying size depending on (A) nAb KD, (B) HIV-
1 entry stoichiometry, T, and (C) mean viron trimer number, Z. Panels (D) to (F) show the
predicted nAb concentrations required to completely neutralize HIV-1 populations of 1, 141
or 9400 virions as a function of (D) nAb KD, (E) HIV-1 entry stoichiometry, T, or (F) the
mean virion trimer number, Z. The required nAb concentration for complete neutralization is
a complex function of T and Z, but linear in KD. This is the case because for a fixed viron popu-
lation size, the fraction of envelope subunits required to be bound by nAb for complete neu-
tralization, fb, is constant (see also Fig 4F).
(PDF)
S11 Fig. Comparison of predicted and experimental nAb neutralization curves. (A) Com-
parison of predicted and experimental nAb neutralization curves for HIV-1 strain BG505
across five nAbs. BG505-specific T, Z and nAb KD values (see S3 and S5 Tables) were used to
predict the neutralization curves. Experimental data were obtained using BG505 pseudovirus
stocks and TZM-bL reporter cells. We find that the predicted neutralization curves are notably
steeper than experimentally obtained curves. (B) Comparison of predicted and experimental
nAb neutralization curves for SHIV strain P3 across three nAbs. P3-specific T, Z and nAb KD
values (see S3 Table) were used to predict the neutralization curves. Experimental data were
obtained using replication-competent SHIV-P3 stocks and PBMC target cells, and were previ-
ously reported [10, 16]. We noted that especially for nAbs PGT121 and b12, predicted and
experimental neutralization curves showed better agreement than for HIV-1 BG505 in (A).
(PDF)
S12 Fig. The trimer number distribution influences Hill coefficient. To follow up the dis-
crepancy between experimental and predicted neutralization curve steepness (i.e., Hill coeffi-
cient; see S11A Fig) we asked which parameter of our model may steer the steepness of the
predicted curves. We found that assuming a broader virion trimer number distribution, i.e. a
higher variance in trimer numbers across virions, results in less steep predicted neutralization
curves. For this graph we used the following parameters: Z ¼ 9:5, T = 2, N = 1, KD = 8.65x10
-9.
Green: Var[η] = 1, black: Var[η] = 33.25, red: Var[η] = 100.
(PDF)
S13 Fig. Statistical model comparison between nAb IC50 predictions of our model and a
simple KD-based model. We defined the nAb KD-based model as a linear model between the
logarithm of the observed nAb IC50s and the logarithm of the nAb KDs. (A) Our model (red
line, shown for T = 3) follows fluctuations in the mean nAb IC50s better (black dots, for the
nAb data see S5 Table) than the KD-based model (green line). (B) Predicted nAb IC50 values
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plotted against the mean of the observed IC50 values are shown in green for the KD-based
model and in red for our model. The visually better performance in predicting IC50 values of
our model in comparison to a KD-based model is statistically confirmed by using the Akaike
Information Criterion (AIC). We obtain lower AIC values for our model (AIC = 9.72 for our
model with T = 2 and AIC = 8.7 for our model with T = 3) compared to an AIC = 11.7 for the
KD-based model. Note that the value for 2G12 (around 5 nM KD) is not an outlier, as a Kolmo-
gorov-Smirnov test for normality shows that the IC50 values are not distributed different from
normal (p-value = 0.16).
(PDF)
S14 Fig. Estimating SHIV-P3 inoculum neutralization in macaque challenge studies. (A)
Predicted neutralization curves for nAbs b12, 2G12, PGT121 and PGT126 against the chal-
lenge virus SHIV-P3. Shaded areas indicate 2-fold variation in nAb KD. Dots depict measured
or extrapolated vaginal nAb concentrations and the coloured areas indicate 2-fold variation in
these nAb concentrations, indicating the SHIV-P3 predicted neutralization ranges achieved in
the three studies. (B) The fraction of predicted non-neutralized SHIV-P3 virions in depen-
dence on mucosal nAb concentrations, as shown in (A).
(PDF)
S15 Fig. Estimating ψ based on in vitro nAb neutralization data. Having obtained similar ψ
estimates across the four analyzed macaque challenge studies using our mechanistic model
(Fig 5), we asked whether similar results could be obtained using solely in vitro nAb neutraliza-
tion data (thus bypassing the need to have estimates for T, Z and nAb KD). We adjusted our
model accordingly, requiring solely nAb IC50 and Hill coefficient as input. In vitro neutraliza-
tion data of SHIV strain P3 with nAbs PGT121, PGT126 and b12 were previously reported
[10, 16] and are shown in S11 Fig. Utilizing these data we obtained a closely matching ψ value
of 2.95x10-5. We thus conclude that (i) the estimate of ψ is likely robust within the range of the
two estimated values (i.e., between 1.65 and 2.95 x10-5), and (ii) in cases where information on
T, Z and nAb KD are missing, in vitro nAb neutralization data may provide a good substitute
to analyze macaque challenge studies as proposed herein.
(PDF)
S16 Fig. Relation between virion trimer number distribution, T and viron infectivity.
Shown are two hypothetical virion trimer number distributions, and how they influence the
fraction of infectious virions in the population in dependence on T. (A) Z ¼ 11:8, Var[η] =
41.3. (B) Z ¼ 11:8, Var[η] = 600.
(PDF)
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